MarketInOut Stock Screener Log In | Sign Up
 

Denali Therapeutics Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 05/29/2026
Denali Therapeutics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization3,324.97 mln
Float144 mln
Earnings Date07/30/2026

Piotroski F-Score

2 / 9
Weak

1-Year Forecast

33.93
Transformational upside

Relative Strength

84 / 100
Strongly outperforming

Debt / Equity

0.04
Debt-free

ROE

-50.64
Deeply negative

Dividend Yield

0.00%
No dividend

Business Description

Denali Therapeutics is a biopharmaceutical company based in South San Francisco, California, focused on developing treatments for brain-related and rare metabolic diseases, including Parkinson's disease, Alzheimer's disease, frontotemporal dementia, and several lysosomal storage disorders. The company has built a broad pipeline of drug candidates that work through a variety of approaches, including enzyme replacement, gene therapy, and small molecule inhibitors. Originally founded in 2013 under the name SPR Pharma, Denali has grown into a clinical-stage company with multiple programs advancing through development, several of which are being pursued in partnership with large pharmaceutical companies.

Key Fundamentals

EPS-2.88
ROE-50.64
ROIC-182
ROA-43.02
EBITDA, mln-532
EV / EBITDA-4.00
EV / EBIT-3.88

Financial Strength

Piotroski F-Score 2 / 9
1-Year Target Price33.93
Short Ratio8.23
Short % of Float9.33

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 9.02% 87 / 100   
1 Month 13.12% 82 / 100   
2 Months 4.21% 61 / 100   
6 Months 9.98% 65 / 100   
1 Year 61.35% 84 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us